What to watch as knee soreness changes during the week

What to check after a sore day

More stairs, yard work, or a long walk may leave your knee sore that evening. A few quieter days may let the ache settle.

Morning stiffness can ease after gentle movement, while swelling may build by evening. Notice whether the same task brings the soreness back.

Long hours in one chair can make the joint stiff. Poor sleep can also make soreness feel harder to bear.

What to discuss before a procedure

Ask what a procedure involves, which risks apply, and when any relief might fade. Your health, medicines, swelling, and earlier care all matter.

QC Kinetix staff in Chandler call their blood-based knee procedures regenerative treatment options. With PRP, or platelet-rich plasma, they spin drawn blood to collect more platelets and guide that part into the joint with a needle.

An exam may show whether this option fits your knee. It can't predict your result.

What to record while the knee changes

Write down how far you walked, how you slept, and whether swelling followed. Use one regular task, such as stairs or getting up from a chair.

Several days give a fairer view than one very good or bad day. Tell the clinician if you walk farther or bend better but swelling remains.

What does this mean for you? Less soreness matters, and simple notes show whether the change lasts.

Sources

1. An individual-participant-data meta-analysis of 621 placebo participants across 10 intra-articular injection trials found placebo response (>=20% pain reduction) was itself predictable: use of local anaesthetic and ultrasound guidance were associated with REDUCED odds of short-term placebo response, and longer trial duration with increased odds at midterm. Any single-arm 'our patients got better' claim about an injection is therefore uninterpretable.

   Zou K, et al. — Predictors of Placebo Response to Local (Intra-Articular) Therapy In Osteoarthritis: An Individual Participant Data Meta-Analysis.. Arthritis Care & Research, 2024. DOI: 10.1002/acr.25212.

2. The RESTORE trial randomized 288 adults aged 50+ with symptomatic mild-to-moderate medial knee OA to three weekly leukocyte-poor PRP injections or saline placebo. At 12 months, pain change was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and medial tibial cartilage volume change was -1.4% vs -1.2% (P=.81). 29 of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings 'do not support use of PRP for the management of knee OA.'

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. In a double-blind, sham-controlled trial of 146 patients aged 35-65 with a degenerative medial meniscus tear and NO knee osteoarthritis, arthroscopic partial meniscectomy produced no significant benefit over sham surgery on any primary outcome at 12 months (Lysholm 21.7 vs 23.3 points; WOMET 24.6 vs 27.1; pain after exercise 3.1 vs 3.3).

   Sihvonen R, Paavola M, Malmivaara A, et al. — Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear.. New England Journal of Medicine, 2013. DOI: 10.1056/NEJMoa1305189.

4. In a placebo-surgery-controlled trial of 180 patients with knee OA, neither arthroscopic debridement nor arthroscopic lavage outperformed placebo surgery at ANY time point over 24 months on any of five self-reported pain/function scales or an objective walking and stair-climbing test.

   Moseley JB, O'Malley K, Petersen NJ, et al. — A controlled trial of arthroscopic surgery for osteoarthritis of the knee.. New England Journal of Medicine, 2002. DOI: 10.1056/NEJMoa013259.

5. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-poor and leukocyte-rich PRP significantly improved 6-12 month WOMAC function versus placebo (MD -10.54 and -13.20 respectively) and both were superior to hyaluronic acid, with leukocyte-poor PRP ranked first (P-score 0.96) — a materially more favourable read of PRP than the RESTORE trial, which is why this corpus presents both.

   Journal of Orthopaedic Surgery and Research authors — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.

6. FDA states verbatim: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production. There are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.